The extensive stage small cell lung cancer market currently has four approved products, among which immune checkpoint inhibitors constitute part of a standard treatment regimen. The approved therapeutic products under immune checkpoint inhibitors include Imfinzi (Durvalumab) and Tecentriq (Atezolizumab), while Zepzelca (Lurbinectedine) constitutes the second-line treatment of extensive stage small cell lung cancer. Cosela (Trilaciclib) is indicated for the treatment of chemotherapy-induced myelosuppression. The primary products that constitute the standard of care (SoC) along with immune checkpoint inhibitors include Etoposide and Cisplatin or Carboplatin. All these three products of SoC have their generics available in the market.

1. Market Definition 

2. Research Scope 

3. Research Methodology 

4. Markets

5. Indication

6. Region

7. Products